Washington

State

Medical

Oncology

Society


Home
About Us
Officers
Membership
Events
Newsletter
Corporate_Member_Events
Practice Issues
Resources
Contact Us
Member List
Legislative Update
Board Members - Password Required


Welcome to the Washington State Medical Oncology Society Website

The purpose of the Washington State Medical Oncology Society (WSMOS) is:

  • To promote the highest professional standards of oncology practice in the state of Washington.
  • To study, research and exchange information, experiences and ideals leading to improvement in the practice of oncology.
  • To represent the practice of oncology and hematology in the state of Washington.

Regularly Monitor the WSMOS Website for:

  • WSMOS meetings & events
  • Legislative updates
  • Billing & reimbursement updates
  • Resources & tools
  • Oncology news
  • Newsletter

Practice Pattern Changes Survey

I know that you are constantly bombarded with survey this and survey that. The link below is another survey, but it is short and straight forward. Further it will be very helpful to WSMOS in establishing priorities as we try and serve you in an era of great flux and uncertainty. I also hope to use it in an ASCO session that I have been asked to chair on the financial challenges in oncology practice. You can be assured that the survey is anonymous, so please be comfortable in being open and frank with any comments. The general results, without comments will be made available on the WSMOS website, and if we have a rapid response, at our Spring Meeting on March 12th.

 

Thank you in advance for your help.

 

Jeffery Ward

President, WSMOS


Click Here to Access the Practice Pattern Changes Survey

Survey of Educational Programs and Oncology Practices

WSMOS recognizes the increasing demand for ARNPs, PAs, RNs, LPNs, and MAs in community, hospital, and academic oncology practice settings.

The American Society of Clinical Oncology (ASCO) has awarded WSMOS a grant to:
1) Survey oncology practices and nursing educators to help understand their respective needs, and to
2) Build a matrix to link practices willing to provide externships and clinical training with programs hoping to expand educational opportunities for their students.

To this end, WSMOS requests your cooperation with this 10 minute survey:


Click Here To Access the Practice Survey 

Click Here to Access the Educators' Survey

Click Here to Access the Current Survey Results

Our Corporate Members

Diamond Level
Amgen
Celgene
Centocor Ortho Biotech
Cephalon Oncology

Genentech
Genomic Health
Lilly Oncology
Millennium Pharmaceuticals
Novartis Oncology

Sanofi-Aventis

Gold Level
Abraxis Oncology
Alexion Pharmaceuticals, Inc.

AstraZeneca Pharmaceuticals
Bayer Healthcare Pharmaceuticals/Onyx
Biogen Idec
Eisai, Inc.
GlaxoSmithKline
McKesson Specialty Care Solutions 
Oncology Supply/ION
OSI Pharmaceuticals Inc.
Pfizer Oncology
US Oncology Physicians Services

Silver Level
Allos Therapeutics, Inc
Genzyme

To Learn More About WSMOS Membership Visit Our Membership Page

 

 

 

 



Latest News from ASCO

Sanofi-aventis Announces Jevtana Approval

Sanofi-aventis is pleased to announce that on June 17, 2010, the US Food and Drug Administration (FDA) approved Jevtana® (cabazitaxel) Injection.

In addition, as of July 19, 2010, Jevtana is now commercially available.

Product related billing information is provided below:

  • National Drug Codes (NDCs)
    • NDC Assigned:    00024-5824-11       
    • Packaging: Carton of one (1) Jevtana vial & one (1) Diluent vial

  • HCPCS Codes
    • J9999     Not otherwise classified (NOC) antineoplastic drugs
    • C9399    Unclassified drugs or biologicals

For more information on Jevtana, please click here for full prescribing information, including boxed WARNING.

Updated VELCADE Label Announced

On January 4, 2010 Millennium announced that the FDA has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term overall survival data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. the VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM). Click Here to read the press release, Click Here to read the Physician Announcement Letter



 

 

 

 

 

 

 

 

 


 

 

This website brought to you by:

 

Washington State Medical Oncology Society
113 W. 7th Street Suite 205
Vancouver, Washington 98660
360.258.0443 Phone 360.695.6937 Fax
wsmos@comcast.net